WANBURY
Back to Income Statement
|
WANBURY Last 5 Year Revenue History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Net Sales | ₹600 Cr | ₹578 Cr | ₹500 Cr | ₹511 Cr | ₹393 Cr |
What is the latest Revenue of WANBURY ?
| Year | Revenue |
|---|---|
| Mar2025 | ₹600 Cr |
| Mar2024 | ₹578 Cr |
| Mar2023 | ₹500 Cr |
| Mar2022 | ₹511 Cr |
| Mar2021 | ₹393 Cr |
How is Revenue of WANBURY Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2025 | ₹600 Cr | 3.77 | |
| Mar2024 | ₹578 Cr | 15.63 | |
| Mar2023 | ₹500 Cr | -2.26 | |
| Mar2022 | ₹511 Cr | 30.23 | |
| Mar2021 | ₹393 Cr | - | |
Compare Revenue of peers of WANBURY
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| WANBURY | ₹664.1 Cr | 13.6% | -12.6% | -22.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹426,662.0 Cr | 2% | -4.4% | 3.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹257,903.0 Cr | 7.1% | 2.5% | 46.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹176,306.0 Cr | 1.4% | -5.7% | 27.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹112,699.0 Cr | 3.6% | 8% | 4.2% | Stock Analytics | |
| CIPLA | ₹111,489.0 Cr | 2% | -0.2% | -14.3% | Stock Analytics | |
WANBURY Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| WANBURY | 13.6% |
-12.6% |
-22.9% |
| SENSEX | 1.8% |
2.3% |
-11.9% |
You may also like the below Video Courses